Antithymocyte globulin (ATG) is accepted as a treatment option for steroid-refractory acute graft-versushost disease (GVHD). We conducted an international survey to determine how steroid refractoriness is defined and how ATG is used in clinical practice. Responses were received from 153 centers in 36 countries. The most common threshold steroid dose to define steroid refractoriness was 2 mg/kg/day (67% of respondents), and the median duration of treatment before failure was declared varied from 3 to 5.5 days, depending on whether failure was defined as 'progressed', 'not improved' or 'not resolved'. The threshold corticosteroid dose was significantly higher in pediatric centers than in adult or combined programs (P = 0.003). ATG was used routinely for treatment of steroid-refractory GVHD by 67% of the respondents. Horse ATG was used more frequently than rabbit ATG overall (50% vs 24%, P Ͻ 0.001), and predominance of horse ATG was most evident in the western hemisphere, in small-to medium-sized centers, and in pediatric centers. A wide variety of dose schedules for both drugs was reported. We conclude that there is some degree of variation in the definition of steroid refractoriness, especially between pediatric and nonpediatric programs, and no consensus has emerged in identifying the optimal ATG dose schedule in this setting. Bone Marrow Transplantation (2001) 28, 945-950. Keywords: graft-versus-host disease; treatment; antithymocyte globulin; antilymphocyte globulin; steroid-refractory; pediatric Antithymocyte globulin (ATG) was first introduced as a therapy for acute GVHD in 1974.
suppressive agents for steroid-refractory GVHD, randomized studies are performed comparing the effectiveness of the new drug to that of ATG. In the present survey, we sought to identify the criteria used by clinical transplant physicians to define when acute GVHD is steroid-refractory, and to examine how ATG is used for treatment of refractory GVHD in blood and marrow transplant centers on a worldwide basis.
Materials and methods
In November 2000, a questionnaire was sent to 410 centers listed as participating in the International Bone Marrow Transplant Registry. Information requested on the questionnaire included the location of the transplant program, patient population, number of allogeneic transplantations performed annually in 1998 and 1999, the working definition of steroid-refractory acute GVHD, whether or not ATG was used for treatment of steroid-refractory acute GVHD, the type of ATG used, the dose schedule and adjuvant medications used with ATG, whether test doses of ATG were administered prior to the treatment dose, and whether the test dose results were utilized clinically. Responses were received from 153 (37%) centers in 36 countries (appendix 1). Characteristics of the responding centers are listed in Table 1 . Responses were received from Table 1 Characteristics of responding centers Responses to the survey were tabulated and compared by the characteristics of the transplant centers responding. Interval data are reported as median and range. The MannWhitney U test and Kruskal-Wallis analysis of variance were used to compare independent samples on an interval scale (days of treatment with steroids, daily steroid dose), and the Fisher exact test and log-likelihood ratio were used for comparisons of categorical data (routine use of ATG, use of ATG by geographic location, dose of ATG by program characteristics). Two-sided P values Ͻ0.05 were considered significant. The analyses were performed using Statistica v5.1 (StatSoft, Tulsa, OK, USA).
Results

Definition of steroid-refractory acute GVHD
Eighty-three centers provided a detailed definition of steroid-refractory acute GVHD. Definitions were categorized as GVHD 'not resolved', 'not improved', or having 'progressed' after a certain duration of treatment with high-dose steroids. The threshold dose for the definition of steroidrefractory acute GVHD was also provided. Thirty-nine percent of the centers included more than one category in the definition (eg either having not resolved after a specific duration of treatment with steroids or having progressed after a specific duration of treatment). Table 2 shows the number of days of treatment and the threshold daily dose of steroids for each categorical definition of steroid-refractory acute GVHD.
For the definition of steroid-refractory, the median duration of treatment with steroids varied from as little as 3 days with progression to as long as 6 days without complete resolution. When compared by program type, there was no significant difference in the number of days of treatment used in the definition of steroid-refractory acute GVHD for any of the categories of the definition (Table 2) . For all centers, the median threshold dose used to define steroid-refractory acute GVHD was 2 mg/kg/day. The daily doses cited most commonly were 2 mg/kg (67%), 5 mg/kg (6%) and 10 mg/kg (5%). There was a significant difference between the pediatric centers and the combined or adult centers in the threshold dose of steroids (Table 2) . When assessed within each category of the definition, there was only a trend for pediatric centers to use a higher threshold dose of steroids in the 'not resolved' and 'not improved' categories, although the small numbers of centers reporting may have limited the power of the analysis.
Use of ATG to treat steroid-refractory acute GVHD
Overall, 67% of the reporting centers indicated that ATG was used routinely for treatment of steroid-refractory GVHD. The proportion of pediatric centers utilizing ATG routinely was significantly higher than for nonpediatric programs (82% vs 63%, P = 0.04). There was no significant difference in use of ATG by program size as defined by the number of patients transplanted annually.
Horse ATG was used routinely for treatment of steroidrefractory acute GVHD by 50% of the centers and rabbit ATG by 24% of the centers (Table 3) . When assessed by patient population, horse ATG was used more frequently than rabbit ATG by combined programs and pediatric centers. When assessed by program size, horse ATG was used more frequently by small-and medium-sized programs. When assessed by location of the program, use of horse ATG predominated over rabbit ATG significantly only in the western hemisphere.
Horse ATG dose schedules
There were 10 dose schedules of horse ATG reported by responding centers (Table 4 ). The average daily dose of horse ATG ranged from 5 mg/kg to 40 mg/kg. The mini-947 Table 3 Use of horse vs rabbit antithymocyte globulin (ATG) mum cumulative dose of ATG was calculated by multiplying the minimum number of days of treatment by the average daily dose. The minimum cumulative dose of horse ATG ranged from 25 mg/kg to 180 mg/kg. The minimum cumulative dose was Ͻ90 mg/kg for 47%, 90 mg/kg for 33%, and Ͼ150 mg/kg for 20% of centers using horse ATG There was a trend for a higher daily dose to be used in pediatric programs (P = 0.07), and there was no correlation between program size and average daily dose of horse ATG.
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Rabbit ATG dose schedules
There were 16 dose schedules of rabbit ATG reported. To simplify analysis, these were recategorized into eight groups (Table 4 ). The average daily dose of rabbit ATG varied from 0.5 mg/kg to у10 mg/kg. The minimum cumulative dose of rabbit ATG varied from 4 to 50 mg/kg. The minimum cumulative dose was Ͻ10 mg/kg for 17% of the centers using rabbit ATG, 10-15 mg/kg for 66%, and Ͼ15 mg/kg for 17%. There was a trend for higher doses of rabbit ATG to be used in nonpediatric centers (P = 0.08), and the variation in doses used did not correlate with the program size.
Administration of ATG
Eighty-seven percent of the centers reported administering premedications for horse ATG and 89% for rabbit ATG. For centers using horse ATG, steroid premedications were used by 74%, antihistamines by 69%, and acetaminophen by 56%. For centers using rabbit ATG, steroid premedications were used by 72%, antihistamines by 50%, and acetaminophen by 50%. Twelve percent of centers using horse ATG reported adding steroids to the infusion, and 11% of those using rabbit ATG added steroids to the infusion. A test dose of ATG by subcutaneous injection or short intravenous infusion prior to the administration of the therapeutic dose of ATG was used at 48% of the centers. This included 54% of the centers using horse ATG and 29% of centers using rabbit ATG (P = 0.04). Interestingly, of the centers using the test dose, 53% of the respondents indicated that ATG was administered even if the test dose was positive.
Discussion
While ATG has been used extensively in the treatment of steroid-refractory acute GVHD, what constitutes steroidrefractory acute GVHD and the optimal dose schedule of ATG for treatment have not been established. We have found that, in clinical practice, a steroid dose of 2 mg/kg/day is used most frequently in the definition of steroid-refractory GVHD, but the minimum duration of treatment varies with whether the GVHD is progressing, not improving or not totally resolved. Further, horse ATG is used more frequently than rabbit ATG, but a wide variety of dose schedules of these drugs are in use.
There are few published studies that address the criteria for the definition of steroid-refractoriness. Oblon et al 11 reported that escalation of the dose of steroids to as much as 10 mg/kg/day resulted in responses in patients with GVHD refractory at lower doses, but the number of patients treated was small. In contrast, both a retrospective comparison 12 and a prospective randomized study 13 showed no additional benefit for use of very high doses of steroids as treatment of GVHD in comparison to 2 mg/kg/day. In addition, although Martin et al 14 showed that some patients treated with standard-dose steroids manifested complete or partial responses as late as 7-14 days of treatment, Van Lint et al 13 reported that a lack of response after as few as 5 days of treatment was associated with a significantly higher treatment-related mortality. In fact, the criteria we have found to be used most frequently for the definition of steroid-refractory reflect the results of Van Lint's study. 13 Our survey also revealed that pediatric programs utilized a higher threshold steroid dose and duration of therapy in the definition of steroid-refractory GVHD in comparison to nonpediatric programs. The rationale for this practice is unclear in the absence of data to support it. It may be, however, that pediatric patients are able to tolerate the sideeffects of prolonged use of high-dose steroids better than adults do, and continued therapy with steroids to capture late responders may not be as deleterious in the pediatric population as it is in adults.
Approximately two-thirds of the responding centers reported using ATG routinely for treatment of steroidrefractory acute GVHD. Interestingly, the highest proportion of centers using ATG routinely was amongst the pediatric programs. For programs not using ATG routinely, the comment section of the questionnaire indicated that investigational drugs were used instead. The predominance of ATG use at pediatric centers could thus possibly reflect the lack of availability of investigational drug protocols for pediatric patients, since drug studies in children are generally delayed until trials have demonstrated safety in adults, if they are performed in children at all.
There are currently 14 formulations of horse or rabbit ATG available in various locations around the world. Different brands of ATG, as well as different lots of the same brand, may have markedly different titers of antibodies directed against specific T cell antigens, 15, 16 suggesting that some formulations may potentially be superior to others. Studies in renal and cardiac transplant recipients have in fact revealed substantial differences in efficacy and toxicity when comparing different brands of ATG for rejection prevention or treatment. [17] [18] [19] [20] We have found that the majority of blood and marrow transplant centers use horse ATG except in Europe. This would appear to be based upon logistical issues (ie availability) as opposed to efficacy, as no studies have compared the use of horse and rabbit ATG in the treatment of acute GVHD. Use of rabbit ATG for treatment of GVHD may also have predominated in centers where horse ATG was used in the preparative regimen, although there is no evidence to contraindicate use of a second course of horse ATG in these patients.
The most striking finding of our survey was the wide range of dose schedules of ATG that was largely independent of the program characteristics. The dose schedules of ATG reported to be active in the treatment of GVHD (15 mg/kg every other day, 15 mg/kg twice daily, and 40 mg/kg/day for horse ATG; and 2.5 mg/kg/day for rabbit ATG) [4] [5] [6] [7] [8] [9] [10] were used by 6-28% of the centers using ATG. The remainder of the dose schedules used appear to be unsupported by peer-reviewed publications.
We also found that a substantial proportion of centers have either abandoned use of the ATG test dose or administered ATG even if the test dose was positive. In solid organ transplant recipients, presensitization to ATG did not appear to adversely affect efficacy, 21 which supports use of ATG in skin test-positive patients. In addition, the steroid and antihistamine premedications used by most centers might ameliorate any potential side-effects from administration of the therapeutic dose of ATG in the face of a positive skin test. The safety of this practice, however, has not been established firmly, so the risk-benefit ratio should be considered seriously when contemplating administration of ATG to a patient without performing a test for presensitization or to a patient in whom the test dose was positive.
A limitation of our study is that only 37% of the centers responded to the survey request, but the information from 153 centers still represents a substantial body of data about the use of ATG in clinical practice. We have observed that there is considerable variation in how and when ATG is used for the treatment of GVHD, and that only some of the practices reported are supported by the literature. The critical information needed to guide the rational design of a dose schedule of ATG is not available, since studies of the pharmacokinetics and pharmacodynamics of ATG in blood and marrow transplant recipients are lacking. Despite the fact that ATG has been in use for many years, application of a development plan as is used for contemporary drugs is required to determine if current outcomes reflect the maximum benefit we can expect from the ATG formulations currently available.
